A Medicinal Chemistry Perspective on Protein Tyrosine Phosphatase Nonreceptor Type 2 in Tumor Immunology DOI
Qi Huang, Linghao Hu, Hao Chen

и другие.

Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Фев. 12, 2025

PTPN2 (protein tyrosine phosphatase nonreceptor type 2) is an important member of the protein (PTP) family. It plays a crucial role in dephosphorylating tyrosine-phosphorylated proteins and modulating critical signaling pathways associated with T-cell receptors, IL-2, IFNγ, various cytokines. In recent years, PTPN2's biological has been clarified, particularly since its association tumor immunology was gradually revealed 2017, making it star target for cancer immunotherapy. The dual inhibitor AC484, which targets both PTP1B, currently undergoing phase I clinical trials. This advancement attracted great interest from researchers to develop new drugs based on unique structure. review outlines structural modification processes PTPN2-targeted agents, focusing primarily inhibitors degraders. Finally, this endeavors provide comprehensive perspective evolving field drug discovery immunotherapy, offering valuable insights future development.

Язык: Английский

A Medicinal Chemistry Perspective on Protein Tyrosine Phosphatase Nonreceptor Type 2 in Tumor Immunology DOI
Qi Huang, Linghao Hu, Hao Chen

и другие.

Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Фев. 12, 2025

PTPN2 (protein tyrosine phosphatase nonreceptor type 2) is an important member of the protein (PTP) family. It plays a crucial role in dephosphorylating tyrosine-phosphorylated proteins and modulating critical signaling pathways associated with T-cell receptors, IL-2, IFNγ, various cytokines. In recent years, PTPN2's biological has been clarified, particularly since its association tumor immunology was gradually revealed 2017, making it star target for cancer immunotherapy. The dual inhibitor AC484, which targets both PTP1B, currently undergoing phase I clinical trials. This advancement attracted great interest from researchers to develop new drugs based on unique structure. review outlines structural modification processes PTPN2-targeted agents, focusing primarily inhibitors degraders. Finally, this endeavors provide comprehensive perspective evolving field drug discovery immunotherapy, offering valuable insights future development.

Язык: Английский

Процитировано

0